Investigador REGINA (Carlos Monge I)

Entrenamiento: Biólogo

Oficina: Escuela Profesional de Medicina

Carretera Panamericana Sur Ex km 300. La Angostura, Subtanjalla, Ica, Perú

joseph.pinto@upsjb.edu.pe

Publicaciones:

1. Pérez I, Castilho L, Goytendia A, Rojas E, Bernal J, Alva J, Coyotupac J, Cortez C, Munive C, Tirado-Hurtado I, Pinto JA. First report of a KELnull phenotype in Peru and a lesson of invisible genetic disparity. Transfus Apher Sci. 2019 May 31. pii: S1473-0502(19)30077-1. doi: 10.1016/j.transci.2019.04.025. [Epub ahead of print] PubMed PMID: 31176642.
2. Pinto JA, Raez LE, Oliveres H, Rolfo CC. Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. Expert Opin Biol Ther. 2019 Jun;19(6):509-515. doi: 10.1080/14712598.2019.1610380. Epub 2019 Apr 29. PubMed PMID: 31002006.
3. Rosas G, Ruiz R, Araujo JM, Pinto JA, Mas L. ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2019 Apr;136:48-55. doi: 10.1016/j.critrevonc.2019.02.006. Epub 2019 Feb 16. PubMed PMID: 30878128.
4. Pinto JA, Pinillos L, Villarreal-Garza C, Morante Z, Villarán MV, Mejía G, Caglevic C, Aguilar A, Fajardo W, Usuga F, Carrasco M, Rebaza P, Posada AM, Tirado-Hurtado I, Flores C, Vallejos CS. Barriers in Latin America for the management of locally advanced breast cancer. Ecancermedicalscience. 2019 Jan 22;13:897. doi: 10.3332/ecancer.2019.897. eCollection 2019. Review. PubMed PMID: 30792814; PubMed Central PMCID: PMC6372299.
5. Pinto JA, Saravia CH, Flores C, Araujo JM, Martínez D, Schwarz LJ, Casas A, Bravo L, Zavaleta J, Chuima B, Alvarado H, Fujita R, Gómez HL. Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. Ecancermedicalscience. 2019 Jan 22;13:896. doi: 10.3332/ecancer.2019.896. eCollection 2019. Review. PubMed PMID: 30792813; PubMed Central PMCID: PMC6372295.
6. Tirado-Hurtado I, Carlos C, Lancho L, Alfaro A, Ponce R, Schwarz LJ, Torres L, Ayudant M, Pinto JA, Fajardo W. Helicobacter pylori: History and facts in Peru. Crit Rev Oncol Hematol. 2019 Feb;134:22-30. doi: 10.1016/j.critrevonc.2018.12.005. Epub 2018 Dec 19. PubMed PMID: 30771870.
7. Pinto JA, Raez LE. Old myths about old patients: the case of non-small cell lung cancer. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S362-S363. doi: 10.21037/tlcr.2018.09.24. PubMed PMID: 30705856; PubMed Central PMCID: PMC6328689.
8. Tirado-Hurtado I, Fajardo W, Pinto JA. DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer. Front Oncol. 2018 Apr 12;8:106. doi: 10.3389/fonc.2018.00106. eCollection 2018. Review. PubMed PMID: 29707520; PubMed Central PMCID: PMC5906527.
9. Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, Morante Z, Araujo JM, Gómez HL, Aguilar A, Bretel D, Flores CJ, Rolfo C. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open. 2018 Apr 13;3(3):e000344. doi: 10.1136/esmoopen-2018-000344. eCollection 2018. PubMed PMID: 29682332; PubMed Central PMCID: PMC5905840.
10. Araujo JM, Gomez AC, Aguilar A, Salgado R, Balko JM, Bravo L, Doimi F, Bretel D, Morante Z, Flores C, Gomez HL, Pinto JA. Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Sci Rep. 2018 Mar 20;8(1):4899. doi: 10.1038/s41598-018-23099-7. PubMed PMID: 29559701; PubMed Central PMCID: PMC5861063.
11. Raez LE, Pinto JA, Schrock AB, Ali SM. EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution? J Thorac Oncol. 2018 Mar;13(3):e33-e34. doi: 10.1016/j.jtho.2017.10.005. PubMed PMID: 29472054.
12. Pinillos L, Pinto JA, Sarria G. History of the development of radiotherapy in Latin America. Ecancermedicalscience. 2017 Nov 30;11:784. doi: 10.3332/ecancer.2017.784. eCollection 2017. Review. PubMed PMID: 29225691; PubMed Central PMCID: PMC5718250.
13. Buleje J, Guevara-Fujita M, Acosta O, Huaman FDP, Danos P, Murillo A, Pinto JA, Araujo JM, Aguilar A, Ponce J, Vigil C, Castaneda C, Calderon G, Gomez HL, Fujita R. Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer. Mol Genet Genomic Med. 2017 Jun 28;5(5):481-494. doi: 10.1002/mgg3.301. eCollection 2017 Sep. PubMed PMID: 28944232; PubMed Central PMCID: PMC5606899.
14. Pinto JA, Mas LA, Gomez HL. High Epidermal Growth Factor Receptor Mutation Rates in Peruvian Patients With Non-Small-Cell Lung Cancer: Is It a Matter of Asian Ancestry? J Glob Oncol. 2017 Jan 18;3(4):429-430. doi: 10.1200/JGO.2016.008201. eCollection 2017 Aug. PubMed PMID: 28831453; PubMed Central PMCID: PMC5560464.
15. Pinto JA, Rolfo C, Raez LE, Prado A, Araujo JM, Bravo L, Fajardo W, Morante ZD, Aguilar A, Neciosup SP, Mas LA, Bretel D, Balko JM, Gomez HL. In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. Sci Rep. 2017 May 8;7(1):1526. doi: 10.1038/s41598-017-01207-3. PubMed PMID: 28484222; PubMed Central PMCID: PMC5431475.
16. Aguilar A, Pinto JA, Araujo J, Fajardo W, Bravo L, Pinillos L, Vallejos C. Control of cervical cancer in Peru: Current barriers and challenges for the future. Mol Clin Oncol. 2016 Aug;5(2):241-245. Epub 2016 Jun 10. PubMed PMID: 27446557; PubMed Central PMCID: PMC4950606.
17. Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):. PubMed PMID: 27075627; PubMed Central PMCID: PMC5256931.
18. Araujo JM, Prado A, Cardenas NK, Zaharia M, Dyer R, Doimi F, Bravo L, Pinillos L, Morante Z, Aguilar A, Mas LA, Gomez HL, Vallejos CS, Rolfo C, Pinto JA. Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. Oncotarget. 2016 Apr 12;7(15):20282-92. doi: 10.18632/oncotarget.7943. PubMed PMID: 26958810; PubMed Central PMCID: PMC4991454.
19. Pinto JA, Araujo J, Cardenas NK, Morante Z, Doimi F, Vidaurre T, Balko JM, Gomez HL. A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. NPJ Genom Med. 2016 Feb 3;1:15015. doi: 10.1038/npjgenmed.2015.15. eCollection 2016. PubMed PMID: 29263808; PubMed Central PMCID: PMC5685288.
20. Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematol Oncol Stem Cell Ther. 2014 Dec;7(4):142-8. doi: 10.1016/j.hemonc.2014.09.007. Epub 2014 Oct 29. PubMed PMID: 25467032.
21. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. PubMed PMID: 24356096; PubMed Central PMCID: PMC3946308.
22. Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2013 Jul 1;19(13):3703-13. doi: 10.1158/1078-0432.CCR-13-0623. Epub 2013 May 22. PubMed PMID: 23697991; PubMed Central PMCID: PMC3727144.
23. Gómez HL, Samanéz C, Campana F, Neciosup SP, Vera L, Casanova L, Leon J, Flores C, de Mendoza FH, Casteñeda CA, Pinto JA, Vallejos CS. Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Hematol Oncol Stem Cell Ther. 2012;5(3):152-7. doi: 10.5144/1658-3876.2012.152. PubMed PMID: 23095791.
24. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795. PubMed PMID: 22683778; PubMed Central PMCID: PMC3693569.
25. Gómez HL, Castañeda CA, Vigil CE, Vidaurre T, Velarde RG, Cruz WR, Pinto JA, Suazo JF, Garcés MR, Neciosup SP, Vallejos CS. Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients. Hematol Oncol Stem Cell Ther. 2010;3(3):109-15. PubMed PMID: 20890067.
26. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Neciosup SP, León M, de la Cruz MA, Vigil CE. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010 Aug 1;10(4):294-300. doi: 10.3816/CBC.2010.n.038. PubMed PMID: 20705562.
27. Gómez HL, Pinto JA, Olivera M, Vidaurre T, Doimi FD, Vigil CE, Velarde RG, Abugattas JE, Alarcón E, Vallejos CS. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. 2011 Feb;20(1):39-45. doi: 10.1016/j.breast.2010.06.009. Epub 2010 Aug 12. PubMed PMID: 20705464.